E-Mail
IMAGE: MRI photos illustrate the green MED diet effect on hepatic fat loss A green Mediterranean (MED) diet reduces intrahepatic fat more than other healthy diets and cuts non-alcoholic fatty liver. view more
Credit: Gut 2021
BEER-SHEVA, Israel.January 18, 2021 - A green Mediterranean (MED) diet reduces intrahepatic fat more than other healthy diets and cuts non-alcoholic fatty liver disease (NAFLD) in half, according to a long-term clinical intervention trial led by Ben-Gurion University of the Negev researchers and a team of international colleagues.
The findings were published in
Gut, a leading international journal focused on gastroenterology and hepatology. Our research team and other groups over the past 20 years have proven through rigorous randomized long-term trials that the Mediterranean diet is the healthiest, says lead researcher Prof. Iris Shai, an epidemiologist in the BGU School of Public Health who is also an adjunct professor at the Harv
E-Mail
An innovative new study is set to examine if changing our mealtimes to earlier or later in the day could reduce the risk of developing Type 2 diabetes.
Led by Dr Denise Robertson, Professor Jonathan Johnston and post graduate researcher Shantel Lynch from the University of Surrey, the study, outlined in the journal
Nutrition Bulletin, will investigate if changing the time we eat during the day could reduce risk factors such as obesity and cholesterol levels that are typically associated with the development of Type 2 diabetes. The team of researchers will also for the first time investigate, via a series of interviews with participants and their friends and family, the impact of such changes on home life, work/social commitments and whether co-habitants of those who make such modifications are influenced to alter their own meal timings/eating habits as a result.
E-Mail
Diabetes is characterized by elevated levels of sugar or glucose (hyperglycemia) in the blood. This occurs due to the lack of the hormone insulin in type 1 diabetes, and to reduced insulin levels in combination with insulin resistance in type 2 diabetes. A recent review of data supports stricter control of hemoglobin A1C levels (HbA1C) among pediatric patients with T1D. This review was led by Dr. Maria J. Redondo, pediatric endocrinologist at Texas Children s Hospital and professor at Baylor College of Medicine, in collaboration with Dr. Sarah Lyons, pediatric endocrinologist at Texas Children s and assistant professor at Baylor College of Medicine, along with other leading endocrinologists and diabetes experts across the U.S.
E-Mail
Bone turnover markers (BTMs) in blood and urine are useful tools in monitoring osteoporosis treatment effects and may be useful for improving patient adherence.
In 2011, a Joint Committee on Bone Metabolism of the International Osteoporosis Foundation (IOF) and the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) designated Procollagen type I N-propeptide (PINP) and the C-terminal telopeptide of type I collagen (β-CTX) in blood as reference bone turnover markers for bone formation and bone resorption, respectively, in osteoporosis. However, the effective clinical implementation of these recommendations requires the standardization/harmonization of commercial assays [1].
As well as a review of the structures of PINP and β-CTX molecules, the authors provide a succinct, referenced summary of current commercial assays, their descriptions, and performance characteristics. Key characteristics and performance specifications of the four commercial
E-Mail
Over the next four years, the international research project SciFiMed aims to develop a biosensor to help better characterise inflammatory reactions in the body. This visionary project, thereby hopes to improve the diagnosis and therapy of various types of inflammatory diseases. SciFiMed is a FET-open project funded by a €3.5 million Horizon 2020 grant from the European Commission. It is led by a consortium of eight European partners from four different countries. Prof. Dr. Diana Pauly University of Marburg has been entrusted with the coordination of SciFiMed ( Screening of inflammation to enable personalised Medicine ).
Prof. Pauly characterises the interdisciplinary project in the following way: An impaired immune system that is unable to combat infection or triggers autoimmune disease places great strain on those affected. SciFiMed combines state-of-the-art diagnostic technology with fundamental immunological research to be implemented in a new type of biosensor co